GlassScriptPhysician profile
Larry Blevins
NPI 1841397452
$11,036.22
in general payments reported to CMS, 2019-2025
8 companies · $968 in 2025
The $968 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $305 · 2022: $2,740 · 2023: $1,347 · 2024: $5,677 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,236 · Travel and Lodging: $2,756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,235.57 |
| Travel and Lodging | $2,755.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $9,924.23 | 2021-2025 | Xeomin |
| Revance Therapeutics, INC. | $556.97 | 2024-2025 | Daxxify |
| Galderma Laboratories, L.P. | $333.68 | 2022-2025 | Dysport |
| Dermavant Sciences, INC. | $127.77 | 2023 | Vtama |
| Innovation Technologies INC | $34.32 | 2022 | |
| Allergan, INC. | $25.04 | 2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $22.07 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $12.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Blevins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.